These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30481563)

  • 1. Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.
    Deng S; Deng Q; Zhang Y; Ye H; Yu X; Zhang Y; Han GY; Luo P; Wu M; Yu Y; Han W
    Cancer Lett; 2019 Feb; 443():1-12. PubMed ID: 30481563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3.
    de Jong EK; de Haas AH; Brouwer N; van Weering HR; Hensens M; Bechmann I; Pratley P; Wesseling E; Boddeke HW; Biber K
    J Neurochem; 2008 Jun; 105(5):1726-36. PubMed ID: 18248618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
    Mueller A; Meiser A; McDonagh EM; Fox JM; Petit SJ; Xanthou G; Williams TJ; Pease JE
    J Leukoc Biol; 2008 Apr; 83(4):875-82. PubMed ID: 18174362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.
    Zhang Y; Gao J; Wang X; Deng S; Ye H; Guan W; Wu M; Zhu S; Yu Y; Han W
    Cancer Biol Ther; 2015; 16(12):1775-83. PubMed ID: 26479470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
    Romagnani P; Maggi L; Mazzinghi B; Cosmi L; Lasagni L; Liotta F; Lazzeri E; Angeli R; Rotondi M; Filì L; Parronchi P; Serio M; Maggi E; Romagnani S; Annunziato F
    J Allergy Clin Immunol; 2005 Dec; 116(6):1372-9. PubMed ID: 16337473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.
    Chheda ZS; Sharma RK; Jala VR; Luster AD; Haribabu B
    J Immunol; 2016 Sep; 197(5):2016-26. PubMed ID: 27465528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression.
    Saahene RO; Wang J; Wang ML; Agbo E; Song H
    Biotech Histochem; 2019 Jan; 94(1):53-59. PubMed ID: 30264586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APC
    Akeus P; Szeponik L; Ahlmanner F; Sundström P; Alsén S; Gustavsson B; Sparwasser T; Raghavan S; Quiding-Järbrink M
    Cancer Immunol Immunother; 2018 Jul; 67(7):1067-1077. PubMed ID: 29671006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Antitumor Mechanism of Paeonol on CXCL4/CXCR3-B Signals in Breast Cancer Through Induction of Tumor Cell Apoptosis.
    Saahene RO; Wang J; Wang ML; Agbo E; Pang D
    Cancer Biother Radiopharm; 2018 Aug; 33(6):233-240. PubMed ID: 29847158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.
    Redjimi N; Raffin C; Raimbaud I; Pignon P; Matsuzaki J; Odunsi K; Valmori D; Ayyoub M
    Cancer Res; 2012 Sep; 72(17):4351-60. PubMed ID: 22798340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice.
    Santodomingo-Garzon T; Han J; Le T; Yang Y; Swain MG
    Hepatology; 2009 Apr; 49(4):1267-76. PubMed ID: 19140218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.
    Wan H; Xu B; Zhu N; Ren B
    Tumori; 2020 Feb; 106(1):55-63. PubMed ID: 31451071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis.
    Erhardt A; Wegscheid C; Claass B; Carambia A; Herkel J; Mittrücker HW; Panzer U; Tiegs G
    J Immunol; 2011 May; 186(9):5284-93. PubMed ID: 21441449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.